Proof-of-principle disease models have demonstrated the feasibility of an intrauterine gene modification therapy (in utero gene therapy (IUGT)) approach to hereditary diseases as diverse as coagulation disorders, haemoglobinopathies, neurogenetic disorders, congenital metabolic, and pulmonary diseases. Gene addition, which requires the delivery of an integrating or episomal transgene to the target cell nucleus to be transcribed, and gene editing, where the mutation is corrected within the gene of origin, have both been used successfully to increase normal protein production in a bid to reverse or arrest pathology in utero. While most experimental models have employed lentiviral, adenoviral, and adenoassociated viral vectors engineered to efficiently enter target cells, newer models have also demonstrated the applicability of non-viral lipid nanoparticles. Amelioration of pathology is dependent primarily on achieving sustained therapeutic transgene expression, silencing of transgene expression, production of neutralising antibodies, the dilutional effect of the recipient's growth on the mass of transduced cells, and the degree of pre-existing cellular damage. Safety assessment of any IUGT strategy will require long-term postnatal surveillance of both the fetal recipient and the maternal bystander for cell and genome toxicity, oncogenic potential, immuneresponsiveness, and germline mutation. In this review, we discuss advances in the field and the push toward clinical translation of IUGT.
Key pointsWhat's already known about this topic? � Transgenic rodent models of monogenic diseases have demonstrated the feasibility and efficacy of intrauterine gene addition therapy.� Diseases most successfully treated in utero in disease models include haemophilia B, neuronopathic Gaucher disease (nGD), surfactant deficiency syndrome, and certain metabolic diseases.� Non-human primate models of haemophilia B have demonstrated long-term safety and sustained transgene expression.